De Phung

5.9k total citations · 1 hit paper
46 papers, 2.0k citations indexed

About

De Phung is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, De Phung has authored 46 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 26 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Cancer Research. Recurrent topics in De Phung's work include Prostate Cancer Treatment and Research (44 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (17 papers). De Phung is often cited by papers focused on Prostate Cancer Treatment and Research (44 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (17 papers). De Phung collaborates with scholars based in United States, Netherlands and United Kingdom. De Phung's co-authors include Andrew Krivoshik, Neal D. Shore, Cora N. Sternberg, Karim Fizazi, Per Rathenborg, Fred Saad, Maha Hussain, Katharina Modelska, Eren Demirhan and Ubirajara Ferreira and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

De Phung

45 papers receiving 2.0k citations

Hit Papers

Enzalutamide in Men with Nonmetastatic, Castration-Resist... 2018 2026 2020 2023 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    2018 677 citations Maha Hussain, Karim Fizazi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
De Phung United States 19 1.7k 618 612 495 357 46 2.0k
Angela Lopez‐Gitlitz United States 14 1.8k 1.0× 676 1.1× 587 1.0× 368 0.7× 297 0.8× 62 1.9k
Mary B. Todd United States 18 2.1k 1.2× 739 1.2× 691 1.1× 605 1.2× 378 1.1× 54 2.5k
Youn C. Park United States 11 2.7k 1.6× 775 1.3× 805 1.3× 785 1.6× 436 1.2× 20 3.1k
Robert Given United States 19 1.7k 1.0× 555 0.9× 474 0.8× 432 0.9× 268 0.8× 57 2.2k
Andrea Juliana Gomes United States 8 1.4k 0.8× 496 0.8× 450 0.7× 336 0.7× 245 0.7× 24 1.5k
Taro Iguchi Japan 18 1.2k 0.7× 443 0.7× 403 0.7× 314 0.6× 237 0.7× 69 1.6k
Albertas Ulys Lithuania 16 1.1k 0.7× 337 0.5× 459 0.8× 323 0.7× 235 0.7× 64 1.4k
Carmel Pezaro United Kingdom 21 1.8k 1.1× 631 1.0× 792 1.3× 498 1.0× 382 1.1× 60 2.2k
Julie S. Larsen United States 13 1.3k 0.8× 494 0.8× 416 0.7× 322 0.7× 234 0.7× 31 1.8k
Diletta Bianchini United Kingdom 22 1.6k 1.0× 755 1.2× 768 1.3× 659 1.3× 233 0.7× 68 2.1k

Countries citing papers authored by De Phung

Since Specialization
Citations

This map shows the geographic impact of De Phung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by De Phung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites De Phung more than expected).

Fields of papers citing papers by De Phung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by De Phung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by De Phung. The network helps show where De Phung may publish in the future.

Co-authorship network of co-authors of De Phung

This figure shows the co-authorship network connecting the top 25 collaborators of De Phung. A scholar is included among the top collaborators of De Phung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with De Phung. De Phung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thaçi, Diamant, Dave Singh, Paul Passier, et al.. (2022). Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis. Journal of Clinical Medicine. 11(23). 7244–7244. 10 indexed citations
2.
Armstrong, Andrew J., Ping Lin, Celestia S. Higano, et al.. (2018). Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. European Urology Oncology. 2(6). 677–684. 25 indexed citations
3.
Hussain, Maha, Karim Fizazi, Fred Saad, et al.. (2018). Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 378(26). 2465–2474. 677 indexed citations breakdown →
4.
Alumkal, Joshi J., Simon Chowdhury, Yohann Loriot, et al.. (2017). Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical Genitourinary Cancer. 15(5). 610–617.e3. 24 indexed citations
5.
6.
Devlin, Nancy, Michael Herdman, Marco Pavesi, et al.. (2017). Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health and Quality of Life Outcomes. 15(1). 130–130. 24 indexed citations
7.
8.
9.
Skaltsa, Konstantina, et al.. (2016). Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology. 12(1). 111–121. 7 indexed citations
10.
Shore, Neal D., Simon Chowdhury, Arnauld Villers, et al.. (2016). Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet Oncology. 17(2). 153–163. 185 indexed citations
11.
Miller, Kurt, David Cella, De Phung, et al.. (2016). Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.. Journal of Clinical Oncology. 34(15_suppl). 5060–5060. 1 indexed citations
12.
13.
Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2015). Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology. 68(5). 787–794. 34 indexed citations
14.
Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2014). Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. The Lancet Oncology. 15(6). 592–600. 71 indexed citations
15.
Skaltsa, Konstantina, Louise Longworth, Cristina Ivanescu, De Phung, & Stefan Holmström. (2014). Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer. Value in Health. 17(2). 238–244. 21 indexed citations
16.
Morris, Michael J., Yohann Loriot, Tomasz M. Beer, et al.. (2014). Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.. Journal of Clinical Oncology. 32(15_suppl). 5054–5054. 2 indexed citations
17.
Efstathiou, Eleni, Mark Titus, Sijin Wen, et al.. (2014). Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(15_suppl). 5000–5000. 29 indexed citations
18.
Schelman, William R., Glenn Liu, George Wilding, et al.. (2009). A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs. 29(1). 118–125. 24 indexed citations
19.
20.
Chodak, Gerald W., Leonard G. Gomella, & De Phung. (2007). Combined Androgen Blockade in Advanced Prostate Cancer: Looking Back to Move Forward. Clinical Genitourinary Cancer. 5(6). 371–378. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Lopez‐Gitlitz Breakdown of academic impact, for papers by Mary B. Todd Breakdown of academic impact, for papers by Youn C. Park Breakdown of academic impact, for papers by Robert Given Breakdown of academic impact, for papers by Andrea Juliana Gomes Breakdown of academic impact, for papers by Taro Iguchi Breakdown of academic impact, for papers by Albertas Ulys Breakdown of academic impact, for papers by Carmel Pezaro Breakdown of academic impact, for papers by Julie S. Larsen Breakdown of academic impact, for papers by Diletta Bianchini
Rankless by CCL
2026